TCGA-D8-A27V-01A-12R-A17B-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 13
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.450
- PROTEIN_SECRETION+0.420
- UV_RESPONSE_DN+0.390
- ESTROGEN_RESPONSE_EARLY+0.350
- ANDROGEN_RESPONSE+0.340
- NOTCH_SIGNALING+0.270
- APICAL_SURFACE+0.230
- WNT_BETA_CATENIN_SIGNALING+0.210
- FATTY_ACID_METABOLISM+0.150
- BILE_ACID_METABOLISM+0.140
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.390
- E2F_TARGETS-0.390
- IL6_JAK_STAT3_SIGNALING-0.310
- G2M_CHECKPOINT-0.290
- INFLAMMATORY_RESPONSE-0.280
- MTORC1_SIGNALING-0.280
- ALLOGRAFT_REJECTION-0.260
- DNA_REPAIR-0.210
- COMPLEMENT-0.190
- SPERMATOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DRR168550 | — | — | 0.772 |
| 2 | dd28c353-13f2-4e6a-a2d7-df94352e043f | — | — | 0.769 |
| 3 | TCGA-E2-A1L6-01A-11R-A13Q-07 | — | A | 0.743 |
| 4 | TCGA-BH-A1ET-01A-11R-A137-07 | — | B | 0.740 |
| 5 | 66290e22-72a1-4af2-93a6-e4859f91a7ef | — | — | 0.740 |
| 6 | TCGA-DK-A1AA-01A-11R-A13Y-07 | — | — | 0.730 |
| 7 | DRR168534 | — | — | 0.728 |
| 8 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.717 |
| 9 | DRR168549 | — | — | 0.713 |
| 10 | SRR8943000 | — | — | 0.705 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.010 | Idelalisib | — uncovered |